Cancel
Dr. Patrick Soon-Shiong
Global Chief Scientific and Medical Officer
@
ImmunityBio
46.070e7l8.3j90ff8ze9x@96fvfv5545e.q55
Sign up to see email
Known information
- Is the Executive Chairman and Global Chief Scientific and Medical Officer at ImmunityBio
- Discussed ANKTIVA® approval in a fireside chat at the Annual Conference of the American Urological Association
- Hosted by Sam S. Chang, Professor of Urology at Vanderbilt Cancer Program during the fireside chat
- Talked about the novel mechanism of how the IL-15 superagonist achieves durable complete responses in BCG unresponsive NMIBC
- Explained the transformation of MHC- to MHC+ could rescue exhausted or immune-evaded T cells as the basis of the Cancer Moonshot announced in 2016
- Presented the QUILT program insights that transforming MHC- to MHC+ applies to all tumor types that have entered the escape phase
- Described ANKTIVA's activation of NK and T cells, resulting in complete durable response
About ImmunityBio
ImmunityBio develops immunotherapy products to enhance the immune system's ability to combat cancer and infectious diseases, offering tailored treatments and conducting extensive clinical trials.
Report inaccurate information
